With the evolution of RAS inhibition, ambitions are high and drug developers are looking for the next big target. TP53 is a noble contender, as it is the most altered gene across solid tumors with no approved targeted therapies and little progress made thus far. The RAS pathway spent four decades on the same “undruggable” list as TP53. Now, KRAS G12C inhibitors have been on the market for five years and pan-RAS and allele-specific agents are in development that, together, could address ~90% of pancreatic cancers, representing a major paradigm shift.
Below are cancers with the top 10 percent prevalences of TP53 alteration.
